Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2930 + Chemotherapy +/- Bevacizumab in HER2-Abnormally Expressed Advanced Colorectal Cancer
NCT07653685Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930 injection + oxaliplatin + capecitabine + bevacizumab in colorectal cancer (CRC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Sep 2026; status: recruiting.
02
Drugs
TQB2930 injection + oxaliplatin + capecitabine + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07653685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653685.